Jeff Huber

Jeff Huber is the Founding CEO of GRAIL. GRAIL's mission is to detect cancer early, when it can be cured.

Jeff is also the Co-Founder & President of OpenCovidScreen (2020-present), a non-profit focused on catalyzing innovation in COVID-19 testing/screening that is Frequent, Fast-turnaround, Cheap, and Easy ("FFCE").

Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google's life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.

Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology companies, including Openwater, Mammoth Biosciences, LytEn, Vir, Sana, Atomwise, Genalyte, Synthego, Apexigen, Tachyon Therapeutics, Mirvie, Pinterest, Honor, OpenDoor, Bolt, and AngelList.

Jeff is a board member of Mammoth Biosciences, Electronic Arts (EA), Upstart (UPST), Openwater, Genalyte (Chairman), Zapata Computing, and the Parker Institute for Cancer Immunotherapy (PICI), and is a former board member of GRAIL (2016-2021; acquired for $10.1B), Aldevron (2019-2021; acquired for $9.6B), Ancestry.com (2018-2020; acquired for $4.7B), Weta Digital (2020-2021; tech assets acquired for $1.625B), and Illumina (ILMN; 2014-2016).

Jeff is an advisory board member for Stanford's Precision Health and Integrated Diagnostics Center (PHIND), Duke University's Research Translation & Commercialization (RTC) Council, and sponsors the 'Huber-Vossough Chancellor’s Chair' in Computational Biomedicine at UC Berkeley.